Progressive disseminated histoplasmosis: The experience in one non-endemic medical center.
epidemiology
histoplasmosis
progressive disseminated histoplasmosis
Journal
Medical mycology
ISSN: 1460-2709
Titre abrégé: Med Mycol
Pays: England
ID NLM: 9815835
Informations de publication
Date de publication:
01 Dec 2023
01 Dec 2023
Historique:
received:
28
08
2023
revised:
19
10
2023
accepted:
08
11
2023
pmc-release:
09
11
2024
medline:
11
12
2023
pubmed:
11
11
2023
entrez:
11
11
2023
Statut:
ppublish
Résumé
Histoplasmosis, the most common endemic mycosis in North America, presents in a myriad of ways, spanning the spectrum from self-limiting pneumonia to progressive disseminated histoplasmosis (PDH). Toward better describing contemporary histoplasmosis syndromes, risks, and outcomes, this single-center retrospective cohort study was performed (2009-2019). The population who developed PDH was similar to that with other forms of histoplasmosis (OFH) except for higher rates of preexisting immunocompromising conditions (91.3% vs. 40%, P < .001) and a trend toward receiving more chronic immunosuppression (65.2% vs. 33.3%, P = .054) compared to those with OFH. Diagnosis was most frequently achieved by urinary or serum antigen positivity. People with PDH more frequently tested positive compared to those with OFH, but negative tests did not rule out histoplasmosis. Median time to diagnosis was prolonged among people with both PDH and OFH (32 vs. 31 days, respectively). Following diagnosis, people with PDH received more liposomal amphotericin (78.3% vs. 20%, P < .001). Subsequent survival at 90 and 365 days and treatment response were similar in both groups. Patients with PDH were more often hospitalized (95.7% vs. 60%, P = .006); however, once admitted, there were no differences in hospital length of stay or intensive care unit admission rate. The challenges of diagnosing histoplasmosis based on clinical presentation alone highlight the need for heightened awareness of these entities especially given the recent reports on expanded endemicity and delays in diagnosis. Histoplasmosis is the most common endemic mycosis in North America. This article summarizes the clinical features, risk factors, and outcomes in patients who developed disseminated disease compared to more localized forms of histoplasmosis.
Autres résumés
Type: plain-language-summary
(eng)
Histoplasmosis is the most common endemic mycosis in North America. This article summarizes the clinical features, risk factors, and outcomes in patients who developed disseminated disease compared to more localized forms of histoplasmosis.
Identifiants
pubmed: 37950559
pii: 7395019
doi: 10.1093/mmy/myad115
pmc: PMC10701471
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NIAID NIH HHS
ID : T32 AI007291
Pays : United States
Organisme : NIH HHS
ID : T32 AI007291-27
Pays : United States
Informations de copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of The International Society for Human and Animal Mycology.
Références
J Clin Microbiol. 2022 Oct 19;60(10):e0112822
pubmed: 36190260
Int J Infect Dis. 2019 Sep;86:147-156
pubmed: 31330326
Emerg Infect Dis. 2016 Mar;22(3):370-8
pubmed: 26890817
Clin Infect Dis. 2011 Sep;53(5):448-54
pubmed: 21810734
Clin Infect Dis. 2020 Mar 3;70(6):1003-1010
pubmed: 31037290
J Fungi (Basel). 2021 Jun 14;7(6):
pubmed: 34198597
J Fungi (Basel). 2022 Apr 23;8(5):
pubmed: 35628693
Emerg Infect Dis. 2011 Sep;17(9):1664-9
pubmed: 21888792
Open Forum Infect Dis. 2020 Aug 17;7(9):ofaa343
pubmed: 32964064
Clin Infect Dis. 2023 Apr 3;76(7):1295-1301
pubmed: 36366776
Clin Microbiol Rev. 2020 Jun 10;33(3):
pubmed: 32522746
Clin Infect Dis. 2020 Sep 12;71(6):1367-1376
pubmed: 31802125
Open Forum Infect Dis. 2016 Feb 15;3(1):ofv219
pubmed: 26894201